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Abstract
Introduction: Flow diversion is a new approach to the endovascular treatment of intracranial aneurysms which uses a high
density mesh stent to induce sac thrombosis. These devices have been designed for the treatment of complex shaped and
large size aneurysms. So far published safety and efficacy data on this approach is sparse.
Material and Methods: Over 8 months, standardized clinical and angiographic data were collected on 70 patients treated
with a flow diverter device (SILK flow diverter (SFD)) in 18 centres worldwide. Treatment and early follow up details were
audited centrally. SFDs were deployed alone in 57 (81%) or with endosaccular coils in 10 (14%) aneurysms, which included:
44 (63%) saccular, 26 (37%) fusiform shapes and 18 (26%) small, 37 (53%) large, 15 (21%) giant sizes. Treatment outcome
data up to 30 days were reported for all patients, with clinical (50 patients) and imaging (49 patients) follow up (median 119
days) data available.
Results: Difficulties in SFD deployment were reported in 15 (21%) and parent artery thrombosis in 8 (11%) procedures.
Procedural complications caused stroke in 1 and serious extracranial bleeding in 3 patients; 2 of whom developed fatal
pneumonias. Delayed worsening of symptoms occurred in 5 patients (3 transient, 1 permanent neurological deficit, and 1
death) and fatal aneurysm bleeding in 1 patient. Overall permanent morbidity rates were 2 (4%) and mortality 4 (8%).
Statistical analysis revealed no significant association between complications and variables related to treated aneurysm
morphology or rupture status.
Conclusion: This series is the largest reporting outcome of the new treatment approach and provides data for future study
design. Procedural difficulties in SFD deployment were frequent and anti-thrombosis prophylaxis appears to reduce the
resulting clinical sequelae, but at the cost of morbidity due to extracranial bleeding. Delayed morbidity appears to be a
consequence of the new approach and warrants care in selecting patients for treatment and future larger studies.
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Introduction
Coil embolisation has proved an effective treatment for most
intracranial aneurysms but larger aneurysms, fusiform shaped
aneurysms, and those with wide necks are technically challenging.
Such aneurysms are also more liable to recurrence which occurs in
20–30% [1] and results in 10–12% of patients requiring
retreatment [2–3]. Adjuvant stenting was proposed in the mid-
1990’s, initially for fusiform aneurysms [4] and more recently to
support the neck region of intracranial saccular aneurysms and to
prevent recurrence [5]. The principle that a stent placed in the
parent artery can reduce blood flow in the sac of an aneurysm to
the point of stagnation and thrombosis has been exploited for
sometime in other anatomies and has now been extended to the
intracranial vasculature in a new range of implants designed to be
sufficiently flexible for intracranial navigation.
These new devices, termed flow diverters, recently became
available for clinical use. The SILK stent (Balt Extrusion,
Montmorency, France) was approved in 2007. This self-expanding
flexible stent is constructed of woven nitinol strands with low
porosity, to retain blood flow in the parent artery and exclude the
aneurysm sac. In order to assess the safety and efficacy of the SILK
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12492flow diverter (SFD), a multicentre registry was established. The
intention of this study is to assess the device’s performance in
routine clinical practice by collecting data from as many users as
possible.
Materials and Methods
Methods
a). Patient recruitment. All centres using the SFD during 8
months (March to November, 2008) were invited to send
anonymised and coded data to the Oxford Neurovascular and
Neuroradiology Research Unit (ONNRU). Thirty centres world-
wide used the device during this period. Eighteen participated and
returned reports of consecutive treatments using a standard case
report form (CRF). The study protocol defining data to be
collected was established prior to recruitment and prior to most
invitations.
Patients were selected for treatment locally at the treating centre
on the basis that the target aneurysm was unsuitable for
conventional endovascular or neurosurgical treatments (see
Figure 1). No details of the patients’ age and gender were
collected to maintain absolute anonymity. The following exclusion
criteria were set by the study Steering Committee: any
contraindication to antiplatelet drugs, pregnancy, breast feeding,
and aneurysms considered treatable with coils alone. The study
protocol was defined as clinical audit using the UK National
Research Ethics Service guidance (Defining Research 2007) and
did not require research ethics committee approval. Each centre
was responsible for obtaining appropriate permissions for data
sharing.
Figure 1. Representative angiograms of aneurysms treated with the SFD. Fusiform vertebral artery aneurysm (a), giant saccular aneurysm at
the vertebro-basilar junction (b), large cavernous carotid artery saccular aneurysm (c) and a recurrent cavernous carotid artery aneurysm (d).
doi:10.1371/journal.pone.0012492.g001
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scores (mRS) and Glasgow Coma Scores (GCS) were recorded.
Therapists were asked to record any untoward procedural events
(UPE) during procedures, any acute clinical complication and a
GCS after treatment. The CRF described UPEs as;
catheterization failure, poor SFD positioning, SFD migration,
poor SFD opening on deployment, haemorrhage during or after
the procedure, complications related to other devices, and partial
or complete thrombosis of the parent artery.
A standard description of the aneurysm to be treated was made.
These details included: rupture status, location, saccular or
fusiform shape, and sac dimensions (neck width, maximum
diameter, and dome to neck length). Details of prophylactic anti-
thrombosis therapies were reported. These included: the dose and
type of drugs used, and the duration of prescriptions.
c). Follow-up protocols. A standard report of each patient’s
clinical status was requested at the time of follow-up imaging. In
order to assess the effectiveness of the SFD at inducing thrombosis,
it was requested that follow-up catheter angiography was
performed 1 month after stopping antiplatelet therapy. The
timing of interval imaging was therefore left to the centres. The
follow-up period range was 9–528 days (median 119 days).
Assessments of the degree of aneurysm thrombosis after SFD
placement were rated as complete occlusion (OG1), neck remnant
(OG2) and residual sac filling (OG3), at end-of-treatment and
follow-up [2].
d). Statistical analysis. Potential associations between the
procedural and delayed complications and the variables related to
aneurysm morphology, presentation, and use of adjuvant coils
were explored using Fisher’s exact test (aneurysm shape, use of
coils, location, and previously ruptured vs unruptured aneurysms)
and the Pearson’s chi-square test (sac size).
Materials
a). Patients. Seventy patients were entered in the study.
Patients’ prior degrees of disability and symptoms due to the
aneurysms were: mRS=0 in 30, mRS=1 in 19, mRS=2 in 12,
mRS=3 in 2, mRS=4 in 6 and mRS=5 in 1 patients. Thus
30(43%) treatments were performed for patients without
symptoms, 31(44%) with symptoms but no or only mild
disability and 9(13%) with moderate or significant disablity i.e.
mRS 3–5.
b). Aneurysms and SFD Sizing. Sixty target aneurysms
were unruptured and 4 of the 10 ruptured aneurysms were treated
within 30 days of haemorrhage. They comprised 44(63%) saccular
and 26(37%) fusiform shapes. There were 15(21%) giant
(.25 mm), 37 (53%) large (10–25 mm) and 18 (26%) small
(,10 mm) aneurysms. Details of target aneurysms are presented in
Table 1. Multiple aneurysms were identified in 5 patients (4 with 2
and 1 with 3 aneurysms). One patient with 2 aneurysms had both
treated with the SFD in separate procedures (without
complication) and another patient was treated for a co-incidental
aneurysm with coils alone at the same procedure. These
treatments have not been included in the analysis of primary
treatment outcomes. The remaining co-incidental aneurysms were
not treated during the study period.
c). Centres. The number of treatments performed in
contributing centres varied from 1–9. Treatments per centre
were: 1 in 2, 2 in 6, 3 in 2, 4 in 1, 5 in 3, 7 in 2, 8 in 1 and 9 in 1.
Thus half the centres performed only 1–3 procedures and for most
these were their first using the SFD.
d). SFD Deployment Technique. Sixty treatments were
performed with SFD alone and 10(14%) with adjuvant
endosaccular coils. Additional coils were used for parent vessel
occlusion during 1 treatment. During the study period many
centres were supported by a proctor introduced by the
manufacturer and treatments were performed under general
anaesthesia according to the current instructions-for-use of the
SFD. Briefly, the technique involves positioning a delivery
microcatheter (Vasco 21, Balt, Montmorency, France) with its
tip distal to the aneurysm and then pushing the SFD, which is
applied to a delivery microwire, to the tip of the delivery
microcatheter. The system is then aligned with the aneurysm
under x-ray fluoroscopy and the SFD deployed by unsheathing it
from the constraint of the microcatheter. This involves a
combination of pushing the delivery wire and retrieving the
Table 1. Aneurysm locations presented as maximum sac size, neck width, and morphology.
Saccular aneurysms (n=44) Fusiform (n=26) Total (n=)
Location of the
aneurysm Maximum dimension (mm) Neck width (mm)
* Maximum dimension (mm)
,10 10–25 .25 ,4 4–10 .10 ,10 10–25 .25
ICA cavernous 1 6 2 1 5 3 2 7
{ 11 9
C O A 58321 2 22101 9
PCoA 1 4 1 1 4 1 0 0 0 6
M C A 1300310116
B A t r u n k 02001111
{ 15
S C A 0100100001
A I C A 0110200002
P I C A 10001001
{ 02
VA 2
{ 1
*,{ 0110205
{ 10
Total (n=) 11 26 7 5 30 8 7 11 8 70
Abbreviations: n (numbers of aneurysms), mm (millimetres), AICA (anterior inferior cerebellar artery), BA (basilar artery), COA (carotid ophthalmic artery), ICA (internal
carotid artery), MCA (middle cerebral artery), PCoA (posterior communicating artery), PICA (posterior inferior cerebellar artery), VA (vertebral artery).
*For one saccular aneurysm the neck width was not measured; {Procedure abandoned (failed treatments);
{Second procedures.
doi:10.1371/journal.pone.0012492.t001
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any resulting fore-shortening. The SFD can be retrieved into the
microcatheter and removed or repositioned when less than 80% of
its length has been extruded. No retrieval is possible thereafter.
e). Antiplatelet regimens. All centres prescribed heparin
and antiplatelets during treatments. Antiplatelet prescriptions in
the majority of patients were a combination of aspirin and
clopidigrel (46 pre-treatment and 49 post-treatment) or aspirin and
dipyridamole (19 pre-treatment and 11 post-treatment). Single
therapy with aspirin (2 pre-treatment and 3 post-treatment) or
clopidigrel (3 pre-treatment and 7 post-treatment) was used in a
minority. Reports of post-treatment prescriptions were incomplete.
Reported intervals to stopping clopidigrel or dipyridamole after
treatments were: after 2 months in 5 patients, after 3 months in 3
patients, after 4 months in 17 patients, after 5 months in 5 patients,
and after 6 months in 9 patients.
Results
a). Procedures
Sixty seven (96%) primary treatments were completed. In 3(4%)
treatments, an SFD could not be deployed for technical reasons
and the procedures were abandoned. These were: failure to
catheterise the aneurysm bearing artery, inability to open the SFD
correctly and failure to advance a long SFD through the delivery
catheter. In the last case, the patient was successfully treated with
two shorter SFDs after the study period ended. Another 3(4%)
patients required repeat procedures because of suboptimal SDF
deployment. In 2, the initial SFD shortened and another SFD was
placed at a second procedure without complication. In the third,
positioning 2 SFDs in a dolichectatic artery failed due to
foreshortening and a second procedure was performed a few days
later with an additional LEO stent (Balt Extrusion). Arterial
patency was confirmed after 48 hours but the patient died from
pneumonia 1 month later.
b). Untoward Procedural Events (UPEs)
One or more UPEs were reported in 20 patients. They were:
12(17%) poor SFD opening on deployment, 7(10%) partial or
complete parent artery thrombosis (PAT), 6(8%) poor SFD
positioning, 4(6%) SFD migration, 3(4%) post procedure extra-
cranial haemorrhages and 1(1.5%) complication related to another
device. No intracranial haemorrhage was reported.
Thus, the commonest UPE was poor SFD opening on
deployment. In 4 procedures, poor SFD positioning and in 3
procedures SFD migrations were concurrently reported. Thus
overall in 15(21%) of procedures SFD deployment difficulties (DD)
were reported and amalgamated for statistical analysis. The
consequences of these events were that 3 patients required repeat
procedures, as described above. In 1 other patient, the operator
decided to occlude the parent artery with coils because of
incomplete SFD opening. This was without clinical worsening.
The 7 reports of PAT occurred together with reports of SFD
DD in 6 procedures (poor opening in 3, positioning in 1 and both
in 2). At the remaining procedure, branch artery thrombosis was
treated successfully with abciximab. Subsequent extracranial
bleeding complicated 3 procedures. In 1 patient this occurred
after endovascular access via the cervical carotid artery. A
resulting neck haematoma was so serious that the patient required
a week of intensive care treatment and the relevant internal carotid
artery was occluded on follow-up angiography. A significant acute
groin haematoma was reported in 1 further patient and 1 patient
developed serious gastric bleeding 48 hours post-procedure and
died of pneumonia 2 weeks later.
c). Procedural Morbidity
The GCS of patients immediately prior to treatment were: GCS
15 n=61 (plus 2 abandoned), GCS 10–14 n=5 (plus 1
abandoned) and GCS,10 n=1. In the 48 hours after treatment,
1 patient worsened (GCS 13 to 5) and 2 patients improved (GCS
14 to 15). Worsening followed a thromboembolic complication,
which caused a new permanent hemiparesis. This was attributed
to thromboembolism caused by adjuvant endosaccular coils. Post-
procedure MRI showed a new infarct in the temporal lobe and
delayed angiography showed the SFD to be patent. There were no
procedural deaths reported in the acute period. However, 2
patients whose treatments were complicated by UPEs, died of
pneumonia within 1 month of the procedure. Thus the immediate
procedural related morbidity was 1 new neurological deficit and 2
deaths.
d). Delayed Morbidity
Follow-up reports on clinical outcomes were returned on
50(71%) patients. Delayed worsening of symptoms and/or new
abnormal neurological signs were reported in 6(12%) of these 50
patients. Transient events in 3 patients occurred within 30 days of
treatment and were attributed to increased mass effect following
aneurysm thrombosis. This caused exacerbation of headaches and
in 2 patients (with aneurysms of the cavernous carotid artery)
worsening opthalmoplegia. Permanent deficits developed in 3
patients and were attributed to delayed thrombosis of the SFD in
the first patient (who developed hemiparesis 10 days post-
procedure), increased mass effect in the second (who developed
a new facial palsy a few days after treatment of a giant basilar
artery aneurysm and died 2 weeks later due to increased brain
stem compression) and delayed aneurysm bleeding in the third
patient. In this last case, follow-up angiography at 5 months
showed residual aneurysm filling. Two months later the patient
experienced increasing headache and acute hemiparesis. CT
showed aneurysm enlargement and acute haemorrhage (Figure 2).
The patient died 4 weeks later despite surgical by-pass. He had
required long-term anticoagulation with warfarin because of a
prosthetic heart valve and remained on aspirin after clopidigrel
was stopped 2 months following SFD deployment.
Thus the overall morbidity reported amongst 50 patients with
follow-up was 2 permanent neurological deficits and 4 deaths, i.e.
morbidity 2(4%) and mortality 4(8%). All clinical complications
are summarized in Table 2.
e). Angiographic outcomes
The end-of-treatment (EOT) assessments of the degree of
aneurysm occlusion for 68 treated aneurysms (67 patients) were:
OG1 in 7(10%), OG2 in 4(6%) and OG3 in 57(84%) aneurysms.
Reports of follow-up angiograms were returned for 49(72%)
aneurysms. The degrees of aneurysm occlusion on follow-up were:
OG1 in 24(49%), OG2 in 13(26%) and OG3 in 12(25%). Thus all
but 2 aneurysms were unchanged or improved on follow up (1
OG1 and 1 OG2 dropped to OG3 on follow up) (Table 3).
Follow up imaging showed parent artery occlusion (PAO) in
7(14%) and a degree of arterial narrowing in 3(6%). Three PAOs
were associated with UPEs (neck haematoma, DD, and deliberate
PAO with coils), 1 was attributed to non-compliancy with
antiplatelet treatment and 3 occurred for no apparent reason.
The degree of arterial narrowing reported in 3 cases was not
graded but reported as severe in 1 patient. In 2 cases of arterial
stenosis on follow up imaging, UPEs had occurred during
treatments (poor SDF opening and thrombosis requiring salvage
abciximab).
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effect of the timing of follow-up imaging was investigated by
dividing the cohort at 20 week intervals post-treatment and
comparing the within-group percentage occlusion grades. This
analysis showed that the proportion of cured aneurysms increased
with time intervals (Table 3 and Figure 3).
f). Statistical Analysis
No statistically significant relationship was found between the
variables related to aneurysm morphology, rupture status, use of
adjuvant coils and the occurrence of procedural and delayed
complications (Table 4).
Discussion
The concept of a stent capable of inducing thrombosis of
intracranial aneurysms has stimulated the development of flow
diverters over the last 15 years. Several researchers have
demonstrated their potential to disrupt endosaccular blood flow
in experimental aneurysms, and systematic haemodynamic studies
have informed their design [6]. These established 70% porosity
(defined as the proportion of open area to total area of the stent) as
the optimum [7]. Lower porosity covered stents have generally
proved too inflexible for intracranial use and results of stent-alone
treatments using conventional high porosity stents have been
inconsistent [8]. Some operators have proposed the use of double
Table 2. Clinical complications observed in patients treated with SFD.
Aneurysm morphology Complications Cause or contributing events Outcome
Location Size (mm) Shape
Procedure related:
BA 13 S Cerebral infarction Thromboembolism attributed to the use of coils Hemiparesis
BA 32 F Pneumonia Patient required second procedure due to
poor SFD positioning
Died
PcomA 32 S Gastric bleeding followed by
Pneumonia
Antiplatelet drugs Died
CCA 35 F Neck hematoma Carotid puncture for EVT and antiplatelets
drugs
Prolonged
ICU stay
MCA 30 F Groin bleeding Antiplatelet drugs Resolved
Delayed complications:
AICA 11 S Worsening of brainstem compression symptoms Aneurysm thrombosis and mass effect Resolved
CCA 27 F Worsening of cranial nerve palsy Aneurysm thrombosis and mass effect Resolved
COA 22 S Worsening of cranial nerve palsy Aneurysm thrombosis and mass effect Resolved
CCA 10 S Parent artery occlusion Poor SFD deployment Hemiparesis
BA 35 F New cranial nerve palsy Aneurysm thrombosis and mass effect Died
MCA 24 F Late increase in aneurysm size and bleeding Uncertain; possible use of warfarin anti coagulation Died
Abbreviations: BA (basilar artery), PcomA (posterior communicating artery), CCA (carotid cavernous artery), MCA (middle cerebral artery), AICA (anterior inferior
cerebellar artery), COA (carotid ophthalmic artery), S (saccular), F (fusiform), EVT (endovascular therapy).
doi:10.1371/journal.pone.0012492.t002
Figure 2. Partially thrombosed aneurysm after treatment with the flow diverter. CT angiograms showing a residual lumen within a large
partially thrombosed fusiform aneurysm of the middle cerebral artery. Follow-up CTA (a) was performed 4 months and (b) 6 months after SFD
(arrows) placement. The second follow-up study shows enlargement of the residual aneurysm lumen (arrow heads) and was performed after a new
haemorrhage (not shown).
doi:10.1371/journal.pone.0012492.g002
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porosity [9] and new covered devices are being tested [10].
Against this background, flow diverters designed with low
porosity and high flexibility were first used in humans in late 2006.
To date, the few reports of their efficacy have been encouraging.
Lylyk et al. [11] reported a series of 53 patients treated in Buenos
Aires using the Pipeline (Chestnut Medical Technologies, Inc.,
Menlo Park, CA). The aneurysm types were predominantly
saccular with only 12% fusiform and nearly half were small in size.
Clinical experience with the same flow diverter was collected on
31 patients treated in the ‘‘Pipeline Embolization Device in the
Intracranial Treatment of Aneurysms (PITA) Trial’’ conducted
between January and November 2007 [12]. One of the 4
contributing centres recently reported on 8 additional aneurysms
[13]. Few procedure-related neurological complications were
reported; a new stroke rate of 6% in the PITA trial and none in
the Buenos Aires report. The latter reported delayed exacerbation
of aneurysm related cranial nerve palsies in 3 patients.
Complication rates reported in this study were similar with only
one acute new neurological deficit despite technical difficulties
associated with SFD deployment in 21% of procedures. Like the
Buenos Aires experience, a minority of our patients developed
delayedneurologicalsymptoms.Thecauseoftransientworseningof
symptoms after induced aneurysm thrombosis is generally attrib-
uted to aneurysm expansion. However, the low porosity of flow
diverterstheoreticallyincreasestheirlikelihoodofoccludingcovered
side branch arteries which might also cause worsening of symptoms
[13]. In this registry, partial or complete parent artery thrombosis
affected 7 procedures and was attributed to the SFD deployment
difficulties rather than inadequate antithrombotic prophylaxes since
theseweregivenduringallthe procedures.However,in1caseitwas
caused by the device covering a large branch artery. A cause of 1
delayed complication was parent artery occlusion found on follow-
up imaging. The relative contribution of aneurysm expansion or
branch artery occlusion in patients developing new neurological
deficits is therefore difficult to assess. Our experience suggests a real
vulnerability of parent artery blood flow after SFD deployment,
perhaps due to a combination of its relatively low radial force and
high metal density, which high dose antiplatelet therapy mitigates.
Treatment using SFDs after acute SAH raises several concerns.
Firstly, after SAH there is a natural reluctance to prescribe
antiplatelets prior to securing the aneurysm against rebleeding. In
the minority of patients treated after acute SAH in this study, it was
the usual practice to withhold prophylaxis with antiplatelet
treatment until the SFD was deployed; accepting a small additional
risk of thrombotic complications. The second issue is the longer
delay to complete thrombosis of the aneurysm after SFD treatment
than after clipping or coiling. During this period, the patient is at
risk of more prolonged bleeding, should the aneurysm re-rupture,
because of antiplatelet medication. One solution is to additionally
pack the aneurysm sack with coils. In this cohort, adjuvant coils
were only used in 1 of the 3 saccular aneurysms treated after acute
SAH. Thus, when it proves difficult or impossible to place coils,
treating physician have to assume that the alteration of local
haemodynamics induced by the SFD reduces the risk of rebleeding.
Currently, there is insufficient experience to prove this assumption.
The relationship between complications and anti-thrombotic
prophylaxis was clear in the patients who suffered haemorrhagic
Table 3. Angiographic outcomes for the aneurysms treated with SFD.
Occlusion
grade
Angiographic
status at EOT
Follow up
available
Occlusion status of aneurysms
at follow up relative to EOT
Angiographic
status at follow up Intervals (weeks) since treatment
0–20 20–40 40–60 60–80
OG1 7 5 OG1, 4; OG2, 0; OG3,1 24 17 3 2 2
OG2 4 4 OG1, 2; OG2, 1; OG3,1 13 13 0 0 0
OG3 57 40 OG1, 18; OG2, 12; OG3,10 12 9 3 0 0
OG1% 10% 10% 49% 44% 50% 100% 100%
95% CI 3–17% 3–17% 35–63% 28–60% 11–89% - -
Angiographic outcomes for the cohort of aneurysms with complete follow up i.e. end of treatment and follow up angiogram.
Abbreviations: OG1 (complete occlusion); OG2 (neck remnant); OG3 (saccular filling).
doi:10.1371/journal.pone.0012492.t003
Figure 3. Timings and results of angiographic follow up. Plot of angiographic outcomes against follow up times in weeks.
doi:10.1371/journal.pone.0012492.g003
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this cohort, patient non-compliance caused delayed spontaneous
artery occlusion and flow disturbances observed during treatments
would probably have resulted in more frequent thrombotic events
without the use of heparin or antiplatelets. Its contribution to the
subsequent evolution of endosaccular thrombosis is unclear and
needs further systematic study. It is tempting to attribute
concurrent long-term anticoagulation and aspirin therapy as the
cause of delayed aneurysm enlargement and haemorrhage, seen in
one patient. On the same basis, antiplatelet therapy might
contribute to symptomatic worsening attributed to sac swelling
observed in the early post-procedure period. Another unanswered
question raised by our results, is whether it is a factor in the
asymptomatic failure of sac occlusion, seen on follow up imaging,
in a minority of aneurysms.
Limitations to this study are incomplete follow-up imaging, no
longitudinal data and the relatively short follow up period. The 50%
rate for complete occlusion up to 3 months is similar to the Buenos
Aires experience [11]. Their longitudinal follow-up suggested that
induced thrombosis was progressive, with the 3-month 56% rate of
complete occlusion rising to 95% at 12 months [11]. Progressive
improvement in occlusion rates were reported by Zentano et al. [14]
and no recurrence was reported for Pipeline treated aneurysms [13].
Our findings are similar but because our data are based on a single
follow up time point, between-patients variations cannot be differen-
tiated from variations over time. The subsequent behaviour of those
aneurysms followed up early is unknown. The aneurysms reported
here comprised a heterogeneous group, with a higher proportion of
fusiform type and posterior circulation aneurysms than the series of
Lylyk et al. or Szikora et al. [11,13]. A concern is two aneurysms whose
occlusion grades dropped relative to the EOT grade and a large study
of sufficient numbers will be needed to show the long-term stability of
thrombosis of different aneurysm types. This concern has resulted in a
recent change in the manufacturer’s instructions for use and the SFD
should now only be used to support embolisation with coils.
The conclusions that can be drawn from the results of this study
need to be considered with reference to its objectives and
methodology. The intention was to collect data on the use of the
SFD during a period when it was being first used in a large number
of hospitals, by experienced practitioners who had either not
previously used the device or had only done so in very few patients.
The centres contributed data on a voluntary basis and deserve
our thanks. A registry can highlight early technical and clinical
problems which would take much longer to identify without
amalgamated data. Complete procedure reports allowed early
recognition of deployment problems leading to a redesign of the
SFD and an alteration in its instructions for use. The associations
tested, though not statistically significant, should help to inform the
designoffuture studies and devices.Severaltechnicalimprovements
have since been made to improve the SFD’s visibility on x-ray
fluoroscopy and deployment control. A new guide pusher has now
been developed in addition to a new radio-opaque marker, which is
more visible than the original version. However, conclusions about
long-term efficacy must be tentative, because a possible bias to
under reporting of poor outcomes cannot be excluded, without
complete follow-up data. Further studies are needed to define the
place of flow diverters in the endovascular treatment of aneurysms
and it is too early to predict their ultimate role.
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Table 4. Effect of patient and procedure related variables on SFD deployment difficulty, flow disturbance, and delayed
neurological complications.
Procedural and
patient variables Deployment difficulty Flow disturbance Delayed neurological complications
Present Absent Present Absent Present Absent
Sac morphology Saccular 9 36 5 40 4 29
Fusiform 6 19 2 23 2 16
p-value 0.76 p-value 1.0 p-value 1.0
Aneurysm size Small 4 18 2 20 3 13
Large 7 30 3 34 2 24
Giant 4 7 2 9 1 8
p-value 0.42 p-value 0.61 p-value 0.56
Coils U s e d 45 18 25
Not used 11 50 6 55 4 40
p-value 0.09 p-value 1.0 p-value 0.18
Location Anterior 12 36 5 43 4 31
Posterior 3 19 2 21 2 14
p-value 0.36 p-value 1.0 p-value 1.0
Untoward events reported during and after treatments related to aneurysm shapes, sizes location, and use of coils.
Deployment difficulty = poor opening, poor positioning, or migration of SFD.
Flow disturbance = partial or complete thrombosis of parent artery.
doi:10.1371/journal.pone.0012492.t004
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